Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2015-11-18 Earnings Release
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
Quarterly financial report / Third quarter financial report
Earnings Release Classification · 95% confidence The document is a 'Business Update' for the third quarter of 2015, which includes financial highlights (cash flow, operating loss, cash position) and operational updates (pipeline progress, management changes). While it contains financial data, it is a summary announcement rather than a full quarterly report. According to the filing definitions, this fits the 'Earnings Release' (ER) category, as it serves as the initial announcement of quarterly financial results and business highlights. 9M 2015
2015-11-18 English
Information financière du troisième trimestre
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly business report from Bone Therapeutics for the period ending September 30, 2015. It contains substantive financial data, including cash flow, operating losses, net losses, and cash position, as well as detailed operational updates on clinical trials and management changes. Since it provides actual financial results for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). 9M 2015
2015-11-18 French
20151118_Q3 2015 update_final.pdf
Earnings Release Classification · 95% confidence The document is explicitly titled "Bone Therapeutics Provides Business Update for the Third Quarter of 2015" and details financial highlights for the first nine months of 2015 (Q3 update). This content structure—a summary of operational progress, pipeline updates, and key financial metrics (cash usage, operating loss, net result) for a specific interim period—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it provides detailed financial highlights and commentary, it goes beyond a simple 'key highlights only' announcement, suggesting a more comprehensive quarterly review. However, the text states it announces the "publication of its trading statement for the third quarter ending 30 September 2015." A 'trading statement' often precedes or is synonymous with an Earnings Release (ER) which focuses on the immediate results. Given the focus on the Q3 period and the nature of the content (business update with financial figures), it aligns best with the Earnings Release (ER) definition, which is the initial announcement of periodical financial results. 9M 2015
2015-11-18 English
20151118_Q3 2015 update_final_FR.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly business report ('rapport d'activité du troisième trimestre 2015') from Bone Therapeutics. It contains substantive financial data, including cash flow, operating losses, net losses, and cash position, as well as operational updates and product pipeline progress. It is not merely an announcement of a report, but the report itself, covering a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim/Quarterly Report (IR). 9M 2015
2015-11-18 French
20151118_Q3 2015 update_final_NL.pdf
Earnings Release Classification · 98% confidence The document is titled "Bone Therapeutics Business Update Derde Kwartaal 2015" (Third Quarter 2015 Business Update). It provides a summary of operational highlights, financial highlights (cash usage, operating loss, net result) for the first nine months of 2015, management commentary, and outlook. This structure—a summary of recent performance and key events for a specific fiscal period (Q3/Nine Months)—is characteristic of an Earnings Release (ER) or potentially an Interim Report (IR). Since it focuses on key highlights and financial figures for a period shorter than a year, and is presented as a 'Business Update' rather than a comprehensive statutory report, it aligns best with the Earnings Release (ER) definition, which covers initial announcements of periodical financial results (key highlights only). It is not a full 10-K, a transcript (CT), or a formal presentation (IP). 9M 2015
2015-11-18 Dutch
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from Bone Therapeutics dated November 12, 2015, announcing that its product ALLOB® received Orphan Drug Designation (ODD) from the EMA and FDA for treating Osteogenesis Imperfecta. This type of announcement, detailing regulatory milestones, scientific progress, and management commentary, is characteristic of an Earnings Release (ER) or a general press release related to corporate/product development. Since it is an initial announcement of a significant regulatory event (ODD) and includes key highlights rather than a comprehensive financial report (like 10-K or IR), the most appropriate classification is Earnings Release (ER), as these often encompass major operational news alongside financial updates, or sometimes Regulatory Filings (RNS) if it were purely administrative. Given the content focuses on a major positive development (ODD) and includes CEO commentary, ER is a strong fit for a significant, non-financial-statement-based announcement. However, since the core event is a regulatory/scientific milestone announcement, and it is not a transcript (CT), a formal report (10-K, IR), or a management discussion (MDA), it fits best under the general category for significant corporate news announcements that aren't strictly financial results releases, which often defaults to RNS or ER. Given the context of biotech announcements, ER is often used for major pipeline updates. If we strictly follow the definitions, it's not a formal 'Earnings Release' (which usually focuses on P&L/Balance Sheet figures), but rather a significant corporate update. Since there is no specific code for 'Regulatory Milestone Announcement', and it is not a short announcement pointing to a full report (RPA), it is best classified as a general Regulatory Filing (RNS) or ER. Given the structure and purpose (announcing a key regulatory achievement), RNS (Regulatory Filings - fallback) is the safest classification for non-standard, yet important, regulatory news that doesn't fit the other specific codes.
2015-11-12 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.